Surveillance of Diversion and Nonmedical Use of Extended-Release Prescription Amphetamine and Oral Methylphenidate in the United States

被引：29
作者：
Sembower, Mark A. [1 ]
Ertischek, Michelle D. [2 ]
Buchholtz, Chloe [3 ]
Dasgupta, Nabarun [4 ]
Schnoll, Sidney H. [2 ]
机构：
[1] Pinney Associates, Pittsburgh, PA USA
[2] Pinney Associates, Bethesda, MD USA
[3] Denver Hlth & Hosp Author, Denver, CO USA
[4] Univ N Carolina, Dept Epidemiol, Gillings Sch Global Publ Hlth, Chapel Hill, NC USA
来源：
JOURNAL OF ADDICTIVE DISEASES | 2013年 / 32卷 / 01期
关键词：
Attention-deficit hyperactivity disorder; amphetamine; methylphenidate; psycho-; stimulants; substance abuse and dependence; OPIOID ANALGESICS; ABUSE; ADHD; MISUSE; TEXAS;
D O I：
10.1080/10550887.2012.759880
中图分类号：
R194 [卫生标准、卫生检查、医药管理];
学科分类号：
摘要：
This article examines rates of nonmedical use and diversion of extended-release amphetamine and extended-release oral methylphenidate in the United States. Prescription dispensing data were sourced from retail pharmacies. Nonmedical use data were collected from the Researched Abuse, Diversion and Addiction-Related Surveillance (RADARS) System Drug Diversion Program and Poison Center Program. Drug diversion trends nearly overlapped for extended-release amphetamine and extended-release oral methylphenidate. Calls to poison centers were generally similar; however, calls regarding extended-release amphetamine trended slightly lower than those for extended-release oral methylphenidate. Data suggest similar diversion and poison center call rates for extended-release amphetamine and extended-release oral methylphenidate.
引用
收藏
页码：26 / 38
页数：13
相关论文
共 22 条
  • [11] The prevalence and correlates of adult ADHD in the United States: Results from the National Comorbidity Survey Replication
    Kessler, RC
    Adler, L
    Barkley, R
    Biederman, J
    Conners, CK
    Demler, O
    Faraone, SV
    Greenhill, LL
    Howes, MJ
    Secnik, K
    Spencer, T
    Ustun, TB
    Walters, EE
    Zaslavsky, AM
    [J]. AMERICAN JOURNAL OF PSYCHIATRY, 2006, 163 (04) : 716 - 723
  • [12] Abuse liability of medications used to treat attention-deficit/hyperactivity disorder (ADHD)
    Kollins, Scott H.
    [J]. AMERICAN JOURNAL ON ADDICTIONS, 2007, 16 : 35 - 44
  • [13] Krenzelok EP, 2003, VET HUM TOXICOL, V45, P325
  • [14] International consensus statement on attention-deficit/hyperactivity disorder (ADHD) and disruptive behaviour disorders (DBDs): Clinical implications and treatment practice suggestions
    Kutcher, S
    Aman, M
    Brooks, SJ
    Buitelaar, J
    van Daalen, E
    Fegert, J
    Findling, RL
    Fisman, S
    Greenhill, LL
    Huss, M
    Kusumakar, V
    Pine, D
    Taylor, E
    Tyano, S
    [J]. EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2004, 14 (01) : 11 - 28
  • [15] LoVecchio Frank, 2004, Prehosp Disaster Med, V19, P185
  • [16] The nonmedical use of prescription ADHD medications: results from a national Internet panel
    Novak, Scott P.
    Kroutil, Larry A.
    Williams, Rick L.
    Van Brunt, David L.
    [J]. SUBSTANCE ABUSE TREATMENT PREVENTION AND POLICY, 2007, 2
  • [17] Signorello Lisa B, 2002, Am J Ther, V9, P199, DOI 10.1097/00045391-200205000-00005
  • [18] Quantifying morbidity associated with the abuse and misuse of opioid analgesics: A comparison of two approaches
    Smith, Meredith Y.
    Schneider, Michael F.
    Wentz, Alicia
    Hughes, Alice
    Haddox, J. David
    Dart, Richard
    [J]. CLINICAL TOXICOLOGY, 2007, 45 (01): : 23 - 30
  • [19] Clinician validation of Poison Control Center (PCC) intentional exposure cases involving prescription opioids
    Smith, Meredith Y.
    Dart, Richard
    Hughes, Alice
    Geller, Anne
    Senay, Edward
    Woody, George
    Colucci, Salvatore
    [J]. AMERICAN JOURNAL OF DRUG AND ALCOHOL ABUSE, 2006, 32 (03) : 465 - 478
  • [20] Visser S. N., 2010, Morbidity and Mortality Weekly Report, V59, P1439
123